AbbVie Inc. ABBV
- Market cap
- $467.4B
- P/E
- 74.7×
Follow ABBV
AbbVie Inc. (ABBV) EV/Sales
As of 25 September 2026, AbbVie Inc. (ABBV) trades at a EV/Sales of 8.3×. Over the past ten years it has ranged from 3.7× (March 2020) to 8.3× (October 2025); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 4.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Annual
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.6× | 14.29% |
| FY2024 | 6.7× | 10.13% |
| FY2023 | 6.1× | 2.97% |
| FY2022 | 5.9× | 7.89% |
| FY2021 | 5.5× | (2.49%) |
| FY2020 | 5.6× | 17.82% |
| FY2019 | 4.7× | (10.80%) |
| FY2018 | 5.3× | (18.67%) |
| FY2017 | 6.5× | 27.44% |
| FY2016 | 5.1× | (1.80%) |
Quarterly
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 7.9× | 10.83% |
| Mar 2026 | 7.1× | (6.41%) |
| Dec 2025 | 7.6× | (3.76%) |
| Sep 2025 | 7.9× | 17.86% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PFE Pfizer Inc. compare | 3.4× |
| AZN AstraZeneca PLC compare | 4.6× |
| NVS Novartis AG compare | 5.6× |
| MRK Merck & Co., Inc. compare | 6.2× |
| JNJ Johnson & Johnson compare | 6.8× |
| GILD Gilead Sciences, Inc. compare | 6.9× |
| AMGN Amgen Inc. compare | 7.0× |
| ABBV AbbVie Inc. | 8.3× |
| LLY Eli Lilly and Company compare | 13.8× |
| Drug Manufacturers General industry median | 4.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on ABBV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement